PDS Biotech Shares Data Update From Ongoing VERSATILE-002 Phase 2 Clinical Trial In Head and Neck Cancer

Majority of patients continue to be followed for survival with multiple patients approaching 3 years

 

Median Overall Survival (mOS) remains at 30 months based on the most recent data cut with approximately six months of additional follow-up

PRINCETON, N.J., June 12, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today provided a data update from its ongoing VERSATILE-002 Phase 2 clinical trial. VERSATILE-002 is evaluating Versamune® HPV + KEYTRUDA® (pembrolizumab) in patients with HPV16-positive head and neck squamous cell cancer ("HNSCC").